23 results about "Cancer development" patented technology

Pyrvinium and its derivatives for reprogramming precancerous mucosa into a noncancerous state are described herein. Furthermore, pyrvinium and its derivatives for reducing the risk of cancer development in organisms containing metaplastic or dysplastic cells are described herein.

Peptides for use in systems that prevent the interaction of the FadA protein released from the Fusobacterium nucleatum (F. nucleatum) bacterium with E-cadherin, which has a carcinogenic effect, or the inhibition of the microorganism with antimicrobial agents and that will inhibit the carcinogenesis mechanisms of F. nucleatum infection and enable the development of therapeutic systems against infections that may occur due to the decreased immunity of patients undergoing cancer treatment with the use of peptides with anti-cancer and antimicrobial properties by developing ten peptides with FadA protein binding energy greater than −11.6 kcal / mol. Peptides with anticancer and antimicrobial properties allow the development of therapeutic systems to prevent F. nucleatum infection, to prevent cancer development after F. nucleatum infection, or to develop therapeutic systems against infections that occur due to the decreased immunity of cancer patients due to cancer treatment.

The application discloses a kind of 2-triazole ethane-1-ketone / alcohol HSP90 / HIF-1 inhibitor and application, new drug use technical field.This kind of inhibitor is transformed from 7-hydroxy new piece helicon A, can low toxicity efficiently inhibit the expression of HIF-1, inhibit tumor cell invasion, clonal proliferation and other malignant development process, in vivo anti-tumor activity experiment and cisplatin can effectively inhibit tumor.This kind of inhibitor can be applied to the preparation of inhibiting cancer development drug.

The invention relates to the field of gene detection, in particular to a molecular marker for diagnosis, screening and risk prediction of early lung cancer. According to the present invention, the substance specifically binding to SPATA18 is selected from one or more of an antibody, a primer or a probe; the substance specifically binding to SPATA18 provided by the invention can realize diagnosis, screening and risk prediction of early lung adenocarcinoma, and fills the blank of risk and prognosis prediction of early non-invasive adenocarcinoma clinically; abnormities on the molecular level can be detected in the early stage of cancer development, and earlier intervention and treatment opportunities can be provided, so that the treatment success rate is increased; according to the method, the number of targets is relatively small, the stability is theoretically higher than that of other multi-target detection after the sample amount is increased, more accurate cancer risk assessment can be provided, the cancer progress probability of a patient can be better predicted, and making of a more accurate treatment plan is facilitated.

Provided herein is a method for detecting a tumour that can be applied to cell-free samples, to cell-free detect circulating tumour DNA. The method utilizes detection of adjacent methylation signals within a single sequencing read as the basic positive tumour signal, thereby decreasing false positives. The method comprises extracting DNA from a cell-free sample obtained from a subject, bisulphite converting the DNA, amplifying regions methylated in cancer (CpG islands, CpG shores, and / or CpG shelves), generating sequencing reads, and detecting tumour signals. To increase sensitivity, biased primers designed based on bisulphite converted methylated sequences can be used. Target methylated regions can be selected from a pre-validated set according to the specific aim of the test. Absolute number, proportion, and / or distribution of tumour signals may be used for tumour detection or classification. The method is also useful in, predicting, prognosticating, and / or monitoring response to treatment, tumour load, relapse, cancer development, or risk.

The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provides an anti-succinate antibody that can serve as a cancer therapeutic agent.

The application provides an isolated circular nucleic acid molecule and a pharmaceutical composition.The isolated circular nucleic acid molecule has a nucleotide sequence shown in SEQ ID NO:1; the pharmaceutical composition comprises: an agent for inhibiting the expression or activity of the circular nucleic acid molecule, wherein the circular nucleic acid molecule has a nucleotide sequence shown in SEQ ID NO:1.The isolated circular nucleic acid molecule plays an important role in regulating the development of cancer, and therefore, the pharmaceutical composition can effectively promote the apoptosis and death of lung cancer cells, for example, cancer; or, when culturing cells in vitro, the pharmaceutical composition can be used to promote the apoptosis of cancer cells.

The present invention relates to a biomarker for predicting the possibility of gastric cancer development and its use, and by measuring the level of mRNA of any one or more genes selected from the group consisting of CDK1, KDF1, CREB5, and AKT2 or the protein expressed therefrom, the possibility of gastric cancer development including metachronous gastric cancer can be predicted. The composition for predicting the possibility of gastric cancer development according to the present invention not only has high accuracy in predicting the development of gastric cancer, but also enables the prediction of gastric cancer by a single measurement method by using multiplex reverse transcription polymerase chain reaction (multi-plex PCR) in one tissue specimen, so it has a high utilization rate. In addition, since it includes a method for quantifying basal gastritis by a quantitative method capable of predicting not only metachronous gastric cancer but also the development of gastric cancer, it provides a method for predicting the risk of gastric cancer development in normal people with a family history or risk factors of gastric cancer. In addition, by predicting the development of metachronous gastric cancer in patients with early gastric cancer treated by endoscopic submucosal dissection, there is an effect that the prognosis of the patient can be predicted.

Compounds were identified from SHP2 Protein Conformational Array (PCA) ELISA. These compounds can disrupt SHP2 Higher Order Structure (HOS) in vitro and induce SHP2 degradation in multiple cancer cell lines. The SHP2-KRAS-ERK pathway analysis indicated that these identified compounds could induce inactivation of the active form of ERK, P-ERK. In addition, some of the compounds can induce SHP2 and / or KRAS degradation in multiple cancer cell lines. Cancer cell line testing demonstrated that these compounds identified through SHP2 HOS disruption showed dose-dependent growth inhibition. Since the SHP2-KRAS-ERK pathway plays an important role in cancer development, these compounds can be used as potential cancer treatments.

PI3Kδ implicates hematologic cancers and solid tumors. Alternative splicing is a post-transcriptional process for acquiring proteomic diversity in eukaryotic cells. Emerging evidence highlights the involvement of aberrant mRNA splicing in cancer development / progression. PI3Kδ-L and PI3Kδ-S are overexpressed in advanced solid tumors, such as prostate, breast, colon, lung and pancreatic cancers. Differential PI3Kδ and PI3Kδ-S expression profiles were identified in a panel of solid tumor cells. PI3Kδ inhibitor Idelalisib and SRPK1 / 2 inhibitor SRPIN340 were employed to assess their efficacies on inhibiting the PI3Kδ-expressing solid tumors. Idelalisib effectively inhibits PI3Kδ-L and its downstream signaling. Idelalisib fails to inhibit PI3Kδ-S activity and its downstream signaling. SRPIN340 reverses the aberrant mRNA splicing, thereby inhibiting the downstream AKT / mTOR signaling. In vitro functional assays further demonstrate that a combination of Idelalisib and SRPIN340 achieve a synergistic drug effect, with drastically reduced cell viabilities / growths of tumor spheroids, in inhibiting the advanced tumor cells.

Provided herein is a method for detecting a tumour that can be applied to cell-free samples, to cell-free detect circulating tumour DNA. The method utilizes detection of adjacent methylation signals within a single sequencing read as the basic positive tumour signal, thereby decreasing false positives. The method comprises extracting DNA from a cell-free sample obtained from a subject, bisulphite converting the DNA, amplifying regions methylated in cancer (CpG islands, CpG shores, and / or CpG shelves), generating sequencing reads, and detecting tumour signals. To increase sensitivity, biased primers designed based on bisulphite converted methylated sequences can be used. Target methylated regions can be selected from a pre-validated set according to the specific aim of the test. Absolute number, proportion, and / or distribution of tumour signals may be used for tumour detection or classification. The method is also useful in, predicting, prognosticating, and / or monitoring response to treatment, tumour load, relapse, cancer development, or risk.

Methods that use a tobacco product to reduce or mitigate some of the negative effects of tobacco consumption, particularly cancer development are described. The tobacco product contains (a) nicotine, (b) at least one of an isothiocyanate or isothiocyanate precursor, (c) myrosinase and (d) a synthetic isothiocyanate. The product can further include at least one of thymoquinone, resveratrol, synthetic vitamin C, thymoquinone resveratrol and a synthetic vitamin C.

The present invention relates to a biomarker composition for cancer diagnosis comprising KSR1 (Kinase Suppressor of RAS1) as an active ingredient. By confirming that the expression of KSR1 (Kinase Suppressor of RAS1) increases in cancer patient groups compared to normal groups, that cancer development is promoted when KSR1 is overexpressed, and that cancer activity is suppressed when KSR1 is knocked down, it was confirmed that the KSR1 or its inhibitor can be utilized for the diagnosis, prevention, treatment, or improvement of cancer or for screening purposes for said disease treatments.

GPR50 (also known as MMR, H9 or ML1X), is an orphan G protein-coupled receptor belonging to the melatonin receptor family, but which has lost the ability to bind melatonin during evolution. Its endogenous ligand has not yet been identified. However, the role of GPR50 in the pathophysiology of various diseases has been described, such as major CNS diseases, major depression, and bipolar disorder. Moreover, recent findings showed that the orphan GPR50 receptor promotes constitutive transforming growth factor-β (TGF-β) receptor signaling and protects against cancer development. Herein the inventors identified the first potent agonists of the orphan GPR50 receptor in a functional cAMP assay. Among these agonist, the 5-methoxy-2-methyl indole (Cp15) which displayed a high agonistic activity at GPR50 receptor (EC50 = 0.5 nM (cAMP), Kd = 174nM (MST)). Intriguingly, replacement of the methyl group in the initially screened 5-methoxy-2-methyl indole with a 2-methylamino group (5-methoxy-2-methylamine indole) (Cp32) resulted in also high agonist potency. In another contribution to define SARs, indole nucleus of Cp15 was replaced by benzofuran (Cp34).

The invention provides methods of detecting a sequence modification (e.g., a genetic fusion or deletion) associated with cancer development that results in expression of a neoantigen. The neoepitope serves as the basis for manufacture of a vaccine, which is administered to a subject to induce an immune response against those cells producing the neoantigen.

A method for identifying the presence of HPV in human tissue may comprise the following steps: collecting a cell from oropharyngeal tissue of a subject utilizing a swab and measuring HPV DNA in the cell or in a solution that contains the contents of the cell. The method may include calculating a risk assessment for the development of cancer in the subject, wherein the risk assessment is calculated from data generated by the measuring of the HPV DNA to determine a persistence of the HPV in human tissue.

The application discloses circular RNA and application thereof. The nucleic acid sequence of the circular RNA comprises a sequence as shown in SEQ ID NO:1. A targeted short nucleic acid molecule designed based on the circular RNA can be used for treating or preventing cancer, especially for treating or preventing lung cancer. The isolated circular nucleic acid molecule of the application plays an important role in regulating cancer development, and by introducing a short nucleic acid molecule targeting the same, apoptosis of cancer cells can be specifically promoted without killing normal cells, so that the short nucleic acid molecule can be used for treating or preventing cancer.

The invention discloses a carborane HSP60 / HIF-1 inhibitor and application, and belongs to the technical field of medicine preparation and new application. A series of novel carborane derivatives HPLC are designed and synthesized, and the series of compounds can efficiently inhibit the expression of HIF-1 by targeting HSP60, show good inhibitory activity on HIF-1HSP60, and inhibit malignant development processes such as tumor cell invasion, clone proliferation and the like. The inhibitor can be applied to preparation of drugs for inhibiting cancer development.

Provided are a risk marker for screening cancers and the use thereof. Specifically, provided is the use of a gene, mRNA, cDNA or protein of a marker for the risk of cancer development or a detection reagent thereof in the preparation of a diagnostic agent or kit for determining the development risk, wherein the cancer risk marker comprises α-MSH. Experiments show that the cancer risk marker can be used as a marker for cancer development, and has high sensitivity and specificity.

The invention relates to the technical field of tumor diagnosis, in particular to a nano preparation for regulating and controlling tumor metabolism and enhancing FDG minimal cancer development as well as a preparation method and application of the nano preparation. In the nano preparation provided by the invention, the glucose oxidase is wrapped in the liposome, the targeting ligand is connected to the surface of the liposome, the targeting ligand can target tumor cells through specific binding to a tumor-associated receptor, and the internally encapsulated glucose oxidase is directionally released in a tumor microenvironment to catalyze local glucose depletion; the cancer cells are forced to activate a stress metabolic pathway and enhance 18F-FDG capture, so that the effect of enhancing PET / CT development of the tumor is achieved, and the inflammatory focus cannot respond to the metabolic pressure due to lack of continuous glycolysis ability, so that the effect of differential diagnosis of cancer and inflammation is achieved.

Providing detection and diagnosis of cancer evolution. [Solution] This disclosure provides a method for determining the probability that a subject's initial condition, for example, the somatic mutation status of a subject with cancer, will develop a subsequent condition after any of a number of therapeutic interventions. Such probabilities can be used to provide healthcare providers with information on a particular treatment process that maximizes the probability of the subject achieving a desired outcome. This disclosure also provides methods and systems for detecting or monitoring cancer evolution. Such methods and systems can be used to predict the development of a patient's response to and resistance to cancer treatment, as well as for other benefits.

The present invention provides compounds and pharmaceutical compositions comprising thereof. Further, methods for increasing or prolonging the therapeutic efficacy of a chemotherapeutic agent in a subject in need thereof, and methods for treating or preventing development of cancer in a subject in need thereof are also provided.